Xention Overview

  • Founded
  • 2002

Founded
  • Status
  • Private

  • Employees
  • 13

Employees
  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Xention General Information

Description

Developer of novel therapies intended to improve the treatment of atrial fibrillation. The company's therapies develop drug candidates that modulate two novel but well-characterized, ion channels to develop breakthrough products in this area of huge unmet medical need, enabling the healthcare industry to use channel-modulating drugs for the treatment of atrial fibrillation, overactive bladder, pain, and autoimmune diseases.

Contact Information

Website
www.xention.com
Formerly Known As
Xention Discovery
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 38 High Street
  • Newmarket
  • Suffolk CB8 8LB
  • England, United Kingdom
+44 01223 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xention Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 000.00 Completed Generating Revenue
8. Later Stage VC 01-Mar-2015 00.000 000.00 Completed Generating Revenue
7. Later Stage VC 18-Oct-2012 00.000 000.00 0000 Completed Generating Revenue
6. Later Stage VC (Series D) 23-Nov-2010 000.00 000.00 Completed Generating Revenue
5. Later Stage VC 25-Jun-2010 000.00 Completed Generating Revenue
4. Later Stage VC 31-Mar-2008 000.00 Completed Generating Revenue
3. Early Stage VC 18-Jul-2005 000.00 000.00 Completed Startup
2. Early Stage VC 10-Sep-2003 $6.34M $12.6M Completed Startup
1. Early Stage VC 01-Aug-2002 $6.24M $6.24M Completed Startup
To view Xention’s complete valuation and funding history, request access »

Xention Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
D Preferred 0,000,000 00.000000 00.0 00.0 00 00.0 00.000
To view Xention’s complete cap table history, request access »

Xention Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapies intended to improve the treatment of atrial fibrillation. The company's therapies develop d
Drug Discovery
Suffolk, United Kingdom
13 As of 2016
000.00
000000 - 000 000.00

000000

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
Brighton, United Kingdom
00 As of 0000
0000
000000 - 000 0000

000000

ing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xention Competitors (83)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom 00 0000 000000 - 000 0000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 0000000000 0 00000
00000000 000000000 Venture Capital-Backed Uppsala, Sweden 00 0000000000
0000000 Venture Capital-Backed Cambridge, MA 000 00000000000 000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 83 competitors. Get the full list »

Xention Patents

Xention Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201215284-D0 Compounds Inactive 28-Aug-2012
GB-201214250-D0 Compounds Inactive 09-Aug-2012
AU-2012338570-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors Inactive 15-Nov-2011 0000000000
CA-2855346-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors Inactive 15-Nov-2011 0000000000
EP-2780343-A1 Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors Inactive 15-Nov-2011 C07D495/04
To view Xention’s complete patent history, request access »

Xention Board Members (15)

Name Representing Role Since
Hugo Slootweg Self Board Member 000 0000
Keith McCullagh Ph.D Self Non-executive Chairman 000 0000
Thomas Casdagli Self Board Member 000 0000
You’re viewing 3 of 15 board members. Get the full list »

Xention Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xention Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seroba Life Sciences Venture Capital Minority 000 0000 000000 0
ABN AMRO Bank Investment Bank Minority 000 0000 000000 0
BTG Corporation Minority 000 0000 000000 0
To view Xention’s complete investors history, request access »